KemPharm, Inc. — Q1 2019 Form 10-Q Summary
Entity note: The filing identifies the registrant as KemPharm, Inc. (Nasdaq: KMPH), while the request metadata names Zevra Therapeutics, Inc. Confirm the intended issuer before relying on this summary.
Business context and reporting period
This unaudited quarterly report covers the three months ended March 31, 2019. KemPharm is a specialty pharmaceutical company developing prodrugs using its LAT technology, primarily for ADHD and stimulant use disorder. Its pipeline included clinical-stage KP415 and KP484, preclinical KP879, and APADAZ, an FDA-approved acute-pain drug licensed to KVK Tech for U.S. commercialization.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.5 million | $11.6 million |
| General and administrative expense | $2.8 million | $3.1 million |
| Total operating expenses / operating loss | $11.4 million | $14.8 million |
| Net loss | $12.3 million | $26.2 million |
| Basic and diluted loss per share | $0.46 | $1.77 |
| Net cash used in operating activities | $11.1 million | $14.1 million |
At March 31, cash and cash equivalents were $13.4 million, restricted cash was $0.5 million, and marketable securities were zero. Total assets were $19.9 million, total liabilities $94.7 million, and stockholders’ deficit $74.8 million. The company reported an accumulated deficit of $233.5 million. With no revenue, gross margin and operating margin are not meaningful.
Convertible-note principal was approximately $83.4 million: $6.7 million under the 9.75% Deerfield note due in 2020 and $76.7 million under 5.50% notes due in 2021. The balance sheet presents convertible notes at a lower carrying amount, net of discounts and related accounting. Operating lease liabilities totaled $2.5 million.
Cash, cash equivalents and restricted cash decreased $5.2 million during the quarter. Investing cash inflow of $3.2 million primarily reflected maturities of marketable securities; financing inflow of $2.7 million primarily came from Lincoln Park equity sales.
Material changes versus the prior comparable period
- Operating expenses fell $3.4 million, led by a $3.1 million reduction in R&D costs, primarily third-party R&D spending.
- Net loss narrowed by $13.9 million. The main driver was the year-over-year swing in derivative and warrant fair-value adjustments: a $0.5 million gain in Q1 2019 versus a $9.7 million loss in Q1 2018. This non-cash item makes the comparison less indicative of underlying operating performance.
- Cash used in operations improved by $3.0 million year over year, while the company continued to consume cash.
- In February 2019, KemPharm began selling shares under its Lincoln Park purchase agreement; by quarter-end it had sold 1.4 million shares for approximately $2.7 million gross proceeds. No shares had been sold under its Second ATM Agreement.
- KemPharm adopted lease accounting standard ASC 842 on January 1, 2019, recognizing approximately $2.6 million of lease assets and liabilities at adoption.
Outlook, management commentary and risks
- Going concern and funding: Management stated that existing resources were expected to fund operating expenses and capital requirements into, but not through, Q3 2019. The filing says recurring losses, negative operating cash flows and stockholders’ deficit raise substantial doubt about the company’s ability to continue as a going concern. Additional financing may not be available on acceptable terms or at all.
- Financing constraints: The company reported approximately $18.5 million of Form S-3 capacity under the applicable 12-month limit, allocated to about $15.3 million for the Lincoln Park agreement and $3.2 million for the Second ATM. Stockholder approval may be required to access part of the purchase-agreement capacity. Equity financing could dilute shareholders.
- Development plans: Management anticipated submitting a 505(b)(2) NDA for KP415 in late Q2 or early Q3 2019. KP484 data and an NDA submission were targeted for 2020. The company was discussing potential partners for its ADHD candidates, aiming to complete the process as early as late Q2 or early Q3 2019.
- APADAZ: KVK’s possible regional pilot launch was anticipated in the second half of 2019; the APADAZ NDA transfer to KVK was completed in February. KemPharm may receive estimated pre-launch payments and cost reimbursements, sales milestones of up to $53 million, and 30%–50% of specified U.S. net profits, subject to contract terms and commercial performance. No Q1 revenue was reported.
- Key risks: Financing availability and runway; clinical and regulatory outcomes, including reliance on the 505(b)(2) pathway; APADAZ launch, market acceptance and partner performance; controlled-substance and opioid-related regulation; manufacturing dependence on third parties; significant debt service and potential dilution.
- Other disclosures: The filing reports no material litigation expected to adversely affect financial condition or results, and no accrual for commitments and contingencies. Management concluded disclosure controls were effective as of March 31, 2019, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for KemPharm, Inc., not an entity named Zevra Therapeutics, Inc.
- Check subsequent financing, cash runway and whether the company obtained enough capital to continue operations beyond the stated Q3 2019 horizon.
- Verify actual KP415 and KP484 regulatory and clinical milestones against the stated targets, and any partnership outcome and terms.
- Track KVK’s APADAZ launch, adoption milestone, sales and resulting payments; the filing’s anticipated launch and potential payments were not guaranteed.
- Review note maturities, interest obligations, covenant restrictions, equity-line usage, dilution and remaining registration capacity.